China Primary-Care Pilot Reform Expands Access in Rural Mountain Counties

Beijing, Aug. 26, 2026 – China’s five-year pilot program for primary health care reform has delivered measurable improvements in rural and mountainous regions, with two national pilot zones reporting stronger specialist networks, faster emergency response, and better chronic-disease management, according to officials at a National Health Commission press conference today.

The Commission launched the “comprehensive pilot zones for primary health care” in 2021 to address infrastructure gaps, upgrade workforce capabilities, and test integrated service models. Beijing’s Miyun District and Sichuan’s Luxian County – both designated as national pilots – have introduced innovations in resource allocation, talent development, and medical-prevention integration, with results now showing in patient access and satisfaction.

Key Takeaways

AttributeDetail
EventNational Health Commission Press Conference
DateAugust 26, 2026
ThemeReform and Innovation in Primary Health Care Pilot Zones
Featured PilotsMiyun District (Beijing), Luxian County (Sichuan)
Key Focus AreasResource allocation, talent training, emergency networks, chronic-care integration
Notable Outcomes基层 visit share rising; emergency response times shortened; chronic mortality down 3.25 pp

Miyun: Mountainous Terrain, Targeted Investment

Miyun, Beijing’s only national primary-care pilot, treats the designation as “a heavy responsibility,” said Zhang Bo, the district’s deputy party secretary. The district party committee established a leading group headed by the party secretary, and health-system performance is now incorporated into the overall party-building assessment.

Fiscal commitment is substantial: health spending has exceeded 13% of the district’s general public budget for three consecutive years, supplemented by nearly CNY 200 million from Beijing municipality to renovate old clinics and acquire new equipment. Over the same period, Miyun recruited 14 senior physicians and 82 university-trained village doctors.

To serve its scattered mountain communities, the district built a sub-regional medical center in the northern mountains, upgrading CT and dialysis units and developing four specialty departments – pain, digestion, blood dialysis, and ophthalmology. In 2025, that center’s annual outpatient visits rose 7.4%. More than 50% of appointments at secondary and tertiary hospitals are now reserved for primary-care referrals, and all grassroots facilities have stroke and chest-pain treatment units. About 30 municipal-level experts rotate weekly to remote clinics via “Internet+ health village” programs.

Luxian: Countywide Network and Digital Dispatch

Sichuan’s Luxian County, a 2021 pilot, has focused on integrating county-township-village resources through a closely knit medical community led by the county people’s hospital, said Wang Bin, party secretary of the medical community. “We unified management, pushed experts down, and linked data up,” Wang said.

The county has dispatched 149 full-time rotational experts to grassroots clinics, set up 46 joint outpatient departments – including gynecology and traditional Chinese medicine – and helped township centers add two hemodialysis rooms and four new clinical departments. More than 60 new techniques, such as laparoscopic hernia repair, are now performed at lower-level facilities.

Digital tools are central: the medical community’s shared imaging, ECG, and ultrasound platforms process remote consultations in real time. To date, nearly 71,500 remote ECG diagnoses, about 60,000 remote imaging reads, and over 1,200 remote ultrasound guidance cases have been completed, enabling mutual recognition of test results across the county.

Emergency care has been overhauled with a proprietary “Huijitong” platform – a ride-hailing-style dispatch system that automatically alerts the nearest ambulance and emergency team when a village doctor makes a one-tap call. Vital signs are transmitted en route, allowing hospital specialists to prepare treatment plans before the patient arrives. Last September, a 42-year-old heart-attack patient in Chaohe Town received emergency care within 4 minutes, reached the county hospital in 29 minutes, and underwent interventional surgery 26 minutes later – a total of 75 minutes from symptom onset to reperfusion.

Chronic-Care Reform: Tiered Management for 200,000+ Patients

Luxian’s party secretary and county magistrate, Zhang Cheng, outlined a chronic-disease management model targeting five conditions – hypertension, diabetes, COPD, lumbar disc herniation, and new strokes within six months – plus locally prioritized additions. A tiered responsibility system assigns hospital directors to geographic areas, family doctors to villages, and specialists to specific diseases. Patients are color-coded red (high-risk), orange (medium), and green (low) for differentiated management.

All 20 township health centers now run integrated chronic-disease outpatient clinics. Since 2020, the county’s premature mortality rate from four major chronic diseases has dropped by 3.25 percentage points. Luxian has invested CNY 1.6 billion to build or renovate 18 medical institutions, adding 126,500 square meters of floor space, and CNY 9 million to equip secondary centers with CT, gastroscope, and automated biochemistry analyzers. A “CT exam within one hour” service circle is now in place.

Frontline Delivery: Faster Visits, Personalized Care

At the community level, Miyun’s Guoyuan Community Health Center serves 75,000 residents. Director Wang Mingfu said the center redesigned its floor plan, placing consultation rooms and lab tests on the same floor and installing self-service kiosks, cutting average visit time by about 30 minutes. It has opened specialty clinics for hypertension, diabetes, osteoporosis, and COPD, and added sleep and gastroenterology clinics with expert support. A “Talk with the Director” and QR-code feedback system helps resolve patient complaints quickly.

Guoyuan also runs a weight-management and sarcopenia-prevention program. Since April 2026, more than 200 overweight residents have received personalized diet-exercise plans using body-composition analysis. Over 2,000 seniors have been screened for sarcopenia; 63 high-risk individuals completed 12-week exercise interventions, with significant improvements in lower-limb strength and balance.

For rural doctors, a training partnership with Peking University First Hospital and Miyun District Hospital has upgraded skills. Wang Rui, a general practitioner at Gaoling Township center, said the six-month program helped her handle emergencies and manage diabetes – citing a 57-year-old asthma patient stabilized and transferred, and a 67-year-old diabetic whose HbA1c dropped from 9.5% to normal with remote insulin adjustment.

Market Impact Analysis

The pilot results carry implications beyond the two demonstration zones. Miyun’s model – combining fiscal prioritization, specialist rotations, and digital referral pathways – offers a template for other mountainous regions with dispersed populations. Luxian’s integrated medical community and automated emergency dispatch system address the perennial challenge of rural-urban service gaps, potentially influencing provincial-level policies across western China.

The chronic-disease management framework, with its color-coded patient stratification and “three packages, four integrations” structure, signals a policy shift from episodic treatment to population-based preventive care. This aligns with national priorities on healthy aging and non-communicable disease control, areas where primary care systems have historically been weak.

For pharmaceutical and medical device suppliers, the expanded specialty services at township centers – including dialysis, imaging, and surgical capabilities – suggest growing procurement demand at the county level. The emphasis on remote diagnostics and data sharing also points to sustained investment in health IT infrastructure.

Forward-Looking Statement

The National Health Commission said it will hold additional press conferences in other pilot zones to share further reform experiences. Industry analysts expect the Commission to distill best practices into national guidelines for primary-care system upgrades, potentially influencing the next five-year health plan.

Miyun and Luxian’s progress in raising grass-roots unit visit shares and reducing chronic mortality offers early evidence that targeted investment and integrated management can yield measurable returns. However, replicating these results across China’s vast and diverse rural landscape – with significant inter-provincial disparities in fiscal capacity and workforce density – remains a formidable challenge. The coming 12–18 months will show whether these pilot models can scale effectively beyond their current geographies.-China Health Reform Pulse

Policy Source: https://www.nhc.gov.cn/xcs/c100122/202608/d4910e8ac75a474e9c86e07732fe6ae0.shtml

Jilin Implements National Essential Medicines List 2026 Identification

Changchun, Aug 25, 2026 — Jilin Province’s Public Resources Trading Center ordered drug marketing authorization holders to verify and confirm essential medicines labeling for all platform-listed products by Sept 30, 2026, as the province prepares to synchronize the 2026 National Essential Medicines List with its procurement systems starting Sept 1.

Policy Snapshot

AttributeDetail
IssuerJilin Public Resources Trading Center
DocumentNotice on the Implementation of the National Essential Medicines List (2026 Edition) Identification
PlatformJilin Medical Insurance Information Platform — Drug and Medical Consumables Procurement Management Subsystem
First sync dateSept 1, 2026 (for products confirmed by Aug 31, 2026)
Hard deadlineSept 30, 2026
ScopeAll online-listed drugs; newly listed products on rolling basis

Implementation Roadmap

  • Phase 1 (by Sept 30, 2026): Enterprises log into the procurement subsystem to confirm or request adjustments to essential medicines attributes for currently listed products. Items verified by Aug 31, 2026 sync to the trading catalog on Sept 1, 2026.
  • Phase 2 (by Sept 30, 2026): Correction requests for mislabeled products processed in batches. No further applications accepted after the deadline.
  • Ongoing: For newly listed products, manufacturers submit essential medicines attributes monthly on the 5th–7th (holidays deferred) during qualification maintenance.

Market Impact Analysis

The Sept 1 synchronization deadline creates a compressed compliance window for pharmaceutical firms operating in Jilin, a northeastern province serving roughly 24 million residents. Companies that fail to verify their National Essential Medicines List status by Sept 30 risk having the trading center assign labels unilaterally, potentially misclassifying products and affecting hospital procurement priority. The two-phase approach—confirmation followed by correction—reflects regulators’ effort to minimize disruption while ensuring the 2026 catalog accurately maps to the province’s online trading system.

For manufacturers, essential medicines designation carries significant commercial weight: listed products receive preferential procurement status in public hospitals and primary care facilities under China’s tiered diagnosis framework. Misclassification could mean exclusion from priority purchasing protocols or, conversely, incorrect inclusion that triggers audit scrutiny. The monthly maintenance window for new listings introduces a predictable rhythm but demands ongoing regulatory vigilance.

Forward-Looking Statement

Industry analysts expect Jilin’s implementation template to be replicated across additional provinces as the 2026 National Essential Medicines List rolls out nationally. The unilateral labeling fallback—where the trading center assigns attributes for non-responsive firms—signals a hardening regulatory stance on compliance automation rather than negotiated accommodation. Pharmaceutical companies with broad national formularies should treat Jilin’s Sept 30 deadline as an early indicator of provincial procurement timelines, with neighboring Heilongjiang and Liaoning likely to issue parallel notices before year-end. The integration of essential medicines attributes directly into procurement transaction catalogs suggests future tenders will increasingly automate prioritization, reducing manual intervention but raising the stakes for data accuracy at the enterprise level.-China Health Reform Pulse

Policy Source: http://www.ggzyzx.jl.gov.cn/jyxx/yxcg/yp/202608/t20260825_3665445.html

Qinghai Adds Flu Vaccines to Non-Immunization Procurement List

Xining, Aug 25, 2026 — Qinghai Province’s Center for Disease Control and Prevention released the second batch of expert demonstration results for its 2026 non-immunization vaccine procurement expansion, clearing three influenza vaccine products for online platform listing after a July 8 expert review session.

Procurement Roster

No.Generic NameDosage FormSpecificationPackagingManufacturerApplicantPrice (CNY)
1Influenza Virus Split VaccineInjection0.5 ml/vialVialHualan Biological Vaccine Inc.Hualan Biological Vaccine Inc.78.00
2Influenza Virus Split VaccineInjection0.25 ml/dosePre-filled SyringeHualan Biological Vaccine Inc.Hualan Biological Vaccine Inc.68.00
3Influenza Virus Subunit VaccineInjection0.5 ml/dosePre-filled SyringeZhongyi Anke Biotechnology Co., Ltd.Zhongyi Anke Biotechnology Co., Ltd.268.00

Regulatory Context

The results follow Qinghai CDC Bureau [2025] No. 39, the provincial implementation plan for centralized online procurement of non-immunization vaccines. The review process encompassed enterprise application, documentation screening, on-site price negotiation, and expert panel certification. All three products were deemed compliant after supplementary materials were submitted. The public comment window runs from Aug 25 to Sept 1, 2026.

Market Impact Analysis

The inclusion of two Hualan Biological split-virus influenza vaccines and one Zhongyi Anke subunit formulation expands Qinghai’s elective flu vaccine portfolio ahead of the autumn immunization season. Hualan’s dual-format offering—vial and pre-filled syringe at 78 yuan and 68 yuan respectively—targets different age groups and procurement budgets, while Zhongyi Anke’s premium subunit vaccine at 268 yuan positions itself as a high-efficacy alternative in a province where vaccine access has historically been constrained by logistics and cold-chain infrastructure.

The 68-yuan to 268-yuan price spread reflects a tiered market strategy, allowing public health facilities to match vaccine selection to patient affordability and clinical indication. For manufacturers, securing slots on Qinghai’s non-immunization procurement platform guarantees formulary access across the province’s public vaccination network, a critical channel in a region with limited private clinic penetration.

Forward-Looking Statement

Industry analysts expect the three products to clear the one-week public comment period without material objections, enabling formal platform listing before the peak flu vaccination window opens in October. The July expert review and August publication timeline suggest Qinghai is front-loading its non-immunization vaccine procurement calendar, potentially signaling earlier-than-usual provincial tendering cycles for 2026. Hualan Biological’s dominant position in this batch—two of three slots—reinforces its standing in China’s seasonal flu vaccine market, while Zhongyi Anke’s subunit entry at a 3.4x price premium tests demand elasticity for advanced influenza formulations in western China.-China Health Reform Pulse

Policy Source: https://www.qhcdc.org.cn/xwzx/tzgg/content_3900